KALA BIO, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $3.9M | $11.2M |
| Selling, general & administrative | — | — | $20.6M | $65.0M | $105.1M |
| Research and development | $18.8M | $22.1M | $18.6M | $17.7M | $11.5M |
| Operating expenses | $39.2M | $41.0M | $39.7M | $85.6M | $141.5M |
| Operating income | -$39.2M | -$41.0M | -$39.7M | -$81.7M | -$130.2M |
| Interest expense | $3.3M | $5.8M | $5.8M | $7.3M | $8.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$27.0M | -$38.5M | -$42.2M | -$44.8M | -$142.6M |
| Balance Sheet | |||||
| Cash and equivalents | $7.6M | $51.2M | $50.9M | $70.5M | $92.1M |
| Current assets | $9.5M | $52.8M | $52.9M | $85.9M | $124.4M |
| Total assets | $9.5M | $55.5M | $55.9M | $86.8M | $139.4M |
| Current liabilities | $2.5M | $17.0M | $8.3M | $25.7M | $37.4M |
| Total liabilities | $2.5M | $43.2M | $48.4M | $67.8M | $122.6M |
| Stockholders' equity | $7.0M | $12.3M | $7.5M | $19.0M | $16.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$32.0M | -$29.4M | -$27.9M | -$78.9M | -$108.2M |
| Depreciation and amortization | $317,000 | $259,000 | $303,000 | $537,000 | $975,000 |
| Stock-based compensation | $7.0M | $8.4M | $7.5M | $7.0M | $16.1M |
| Impairments | $549,000 | $0 | $0 | — | — |
Shares outstanding 18.6M · Free float 58.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.